,
Tye-Din, Jason A.
Daveson, A. James M.
Goldstein, Kaela E.
Hand, Holly L.
Neff, Kristin M.
Goel, Gautam
Williams, Leslie J.
Truitt, Kenneth E.
Anderson, Robert P.
Funding for this research was provided by:
ImmusanT, Inc.
Article History
Received: 23 August 2020
Accepted: 27 October 2020
First Online: 26 November 2020
Ethics approval and consent to participate
: The study was conducted in accordance with the International Conference on Harmonisation for Good Clinical Practice. Local ethics committees approved the study (AUS: Melbourne Health Human Research Ethics Committee, Parkville VIC; Bellberry Limited, Eastwood SA; Uniting Care Health, Eastwood SA; NZ: Central Health and Disability Ethics Committee, Thorndon, Wellington; US: Copernicus Group IRB, Cary NC; Columbia University IRB, New York NY; Mayo Clinic IRB, Rochester MN and The University of Chicago IRB, Chicago IL) See Additional file: Table S9 for additional details. Written, informed consent was obtained from each patient included in the study.
: Not applicable
: GG, KEG, HLH, KMN, KET, LJW and RPA were former employees of ImmusanT, Inc. JAT-D and AJMD served as advisors to ImmusanT, Inc. RPA is the inventor of patents, owned or licenced by ImmusanT, Inc., relating to the diagnostic application of gluten challenge.